Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3

CourtCalifornia Court of Appeal
DecidedFebruary 21, 2025
DocketG063498
StatusUnpublished

This text of Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3 (Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3, (Cal. Ct. App. 2025).

Opinion

Filed 2/21/25 Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3

NOT TO BE PUBLISHED IN OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

FOURTH APPELLATE DISTRICT

DIVISION THREE

VIVERA PHARMACEUTICALS, INC., et al., G063498 Plaintiffs and Respondents, (Super. Ct. No. 30-2021- v. 01207052)

GD LABORATORY CONSULTING, OPINION LLC, et al.,

Defendants;

BLAINE HOLDING & DEVELOPMENT, LLC,

Claimant and Appellant.

Appeal from an order of the Superior Court of Orange County, Nathan Scott, Judge. Affirmed. Motion to strike denied. Law Offices of Mark J. Yost and Mark J. Yost for Claimant and Appellant. Law Office of Saied Kashani and Saied Kashani for Plaintiff and Respondent Vivera Pharmaceuticals, Inc. Paul Edalat, in pro. per., for Plaintiff and Respondent Paul Edalat. * * * Blaine Holding & Development, LLC asserted a judgment lien in the underlying litigation and appeals from a trial court order approving the litigants’ settlement of a business dispute. The order resulted in no recovery on the lien, and Blaine contends the court erred as a matter of law by approving the settlement. We are not persuaded that an abuse of discretion occurred, and we affirm the order. FACTS I. PRELITIGATION EVENTS In April 2021, the parties in this matter—Vivera Pharmaceuticals, Inc., GD Laboratory Consulting, LLC, and others—formed a joint business venture named Focal Point Laboratories, LLC, to operate a business that provided testing for COVID-19. The business did not operate beyond June 2021, and, on June 22, 2021, Vivera’s chief executive officer, Paul Edalat, withdrew $600,000 from Focal Point’s bank account. II. THE UNDERLYING LITIGATION The next day, June 23, 2021, Vivera initiated the underlying litigation by filing a complaint against Focal Point and others, alleging a single cause of action for accounting. The next day, Focal Point filed its own complaint against Vivera and others, and the two lawsuits were ultimately consolidated. For purposes of this appeal, Vivera and Edalat ultimately filed

2 an operative second amended complaint that alleged six causes of action. Of those, Vivera was the plaintiff for two: an accounting cause of action and a fraudulent concealment cause of action—Edalat alone asserted the other four. In July 2021, the trial court issued an order on the parties’ stipulation to appoint a receiver to take possession of Focal Point’s assets and manage them during litigation (the receivership order). Inter alia, the receivership order approved the parties’ stipulation to establish the receivership estate as “monies generated” during a “Covered Time Period,” starting in March 2021 and ending in June 2021. Around the same time, in a different lawsuit, Blaine secured a September 2021 judgment for about $400,000 against Vivera, based on a breach of a lease contract. Based on that judgment, Blaine filed a November 2021 notice of lien in this matter, pursuant to Code of Civil Procedure section 1 708.410, which we quote from further below. In May 2023, Focal Point filed a motion to enforce the receivership order. Specifically, Focal Point asked the trial court to order Vivera to transfer to the receiver the $600,000 Edalat had withdrawn in June 2021. The court granted the motion by ordering Vivera to deliver the money to the receiver within 10 days (the return order). Vivera never sent the money to the receiver. Instead, two months later, in October 2023, Vivera, Edalat, Focal Point, and several other litigants reached a settlement of this matter. Inter alia, the parties agreed that: (1) the parties would mutually release claims against each other; (2) Focal Point

1 All further undesignated statutory references are to the Code of Civil Procedure.

3 would receive $1.5 million from the money in the receiver’s possession; (3) Edalat would receive $600,000 from the same source; and (4) Vivera would not receive any money “because it ha[d] already received the $600,000 from Focal Point prior to the filing of th[e] action” underlying this appeal. The parties’ settlement agreement was explicitly conditioned upon the trial court’s approval, “due to the existence of liens.” Accordingly, Vivera filed a motion for the court’s approval of the settlement, stating that the “$600,000 represent[ed] roughly a third of the net joint venture profits and [was] a reasonable approximation of Vivera’s contractual 33% share of said profits.” Blaine did not dispute the characterization and instead asserted it was an irrelevant point, particularly given Vivera’s wrongful noncompliance with the return order. After considering filings and oral arguments, the trial court granted the motion to approve the settlement and did not provide for payment on Blaine’s lien (the approval order). The court found that “the parties [did] not inequitably structure[ ] the settlement to evade liens or play favorites among judgment creditors.” The court reasoned that “Vivera receive[d] nothing by the settlement other than a release” and explained that even if Vivera had complied with the return order prior to the parties’ settlement (by returning the $600,000 previously withdrawn), the court would still arrive at the same decision to approve the settlement. Blaine 2 timely appealed.

2 We agree with the parties that the approval order is appealable. (See Bank of California v. Thornton–Blue Pacific, Inc. (1997) 53 Cal.App.4th 841, 843–846 [trial court order deciding priorities of competing claims to litigant’s money appealable was final judgment “in legal effect”].)

4 DISCUSSION Blaine contends that we should review the approval order de novo and conclude it was erroneous because the ruling is “directly contrary to the plain language and purpose of [s]ection 708.410 et seq.” and “permit[s] a judgment debtor to benefit financially while evading a valid lien.” I. STANDARD OF REVIEW AND APPELLATE REVIEW PRINCIPLES We review the application of statutory language to undisputed facts de novo and an exercise of discretion for abuse of discretion. (Pangborn Plumbing Corp. v. Carruthers & Skiffington (2002) 97 Cal.App.4th 1039, 1048–1049 (Pangborn).) “An abuse of discretion standard generally applies to a decision concerning the approval of a settlement under section 708.440.” (Oldham v. California Capital Fund, Inc. (2003) 109 Cal.App.4th 421, 430 (Oldham), citing Pangborn, supra, at p. 1048.) Generally, “[d]iscretion is abused in the legal sense whenever, in its exercise, a court exceeds the bounds of reason, all the circumstances before it being considered. [Citation.]” (Nicoletti v. Lizzoli (1981) 124 Cal.App.3d 361, 366–367.) II. GOVERNING LAW The Enforcement of Judgments Law (EJL; § 680.010 et seq.) contains section 708.410, which authorizes “[a] judgment creditor” to impose a lien based on “a money judgment against a judgment debtor who is a party to a pending action or special proceeding.” (§ 708.410, subd. (a).) Two targets are specified: under subdivision (a)(1), a lien can be enforced against “[a]ny cause of action of such judgment debtor for money or property that is the subject of the action or proceeding”; and under subdivision (a)(2), a lien can also be enforced against “[t]he rights of such judgment debtor to money or

5 property under any judgment subsequently procured in the action or proceeding.” The statute is one of eight in article 5, chapter 6, division 2, title 9, part 2 of the Code of Civil Procedure (see §§ 708.410–708.480), all relating to the assertion of a judgment lien in a pending action or proceeding.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Abatti v. Eldridge
112 Cal. App. 3d 411 (California Court of Appeal, 1980)
Nicoletti v. Lizzoli
124 Cal. App. 3d 361 (California Court of Appeal, 1981)
Oldham v. California Capital Fund, Inc.
134 Cal. Rptr. 2d 744 (California Court of Appeal, 2003)
Bank of California v. Thornton-Blue Pacific, Inc.
53 Cal. App. 4th 841 (California Court of Appeal, 1997)
Pangborn Plumbing Corp. v. Carruthers & Skiffington
119 Cal. Rptr. 2d 416 (California Court of Appeal, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vivera-pharmaceuticals-v-gd-laboratory-consulting-ca43-calctapp-2025.